Early Trials

Flagship’s cTA™ Platform and Decision Support Process establish a clear biomarker strategy for your drug development programs.

Exploratory & Efficacy Endpoints

Enable critical go/no-go decisions based on confirmation of action.

Flagship is the ideal partner when you need to understand complex biology in tissue context to:

  • Understand complex pharmacodynamic changes to evaluate efficacy hypothesis, and
  • Make critical go/no-go decisions based on confirmation of action.

Flagship strengthens early pipeline decisions by:

  • Creating fit-for-purpose assays to evaluate pharmacodynamic or surrogate efficacy responses in tissue context.
  • Leveraging Flagship’s proprietary tissue interpretation platform and cross-disciplinary expertise to elucidate biomarker information.

Flagship’s technology is fully developed, clinically validated and empowered by scientific and operational expertise

proven success

There are pre-proof of concept clinical trials that are about getting proof of science and technology…..this is where I partner with Flagship.

-Senior Director, Oncology Research, large pharma company

SOLVE DIFFICULT TISSUE ANALYSIS CHALLENGES WITH OUR UNIQUE APPROACH

Work With Us

Breadth and depth in people and technology to deliver on any challenge
Work With Us